Medical/Pharmaceuticals

Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL

SHANGHAI, Sept. 14, 2023 /PRNewswire/ -- Dizal today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for golidocitinib for the treatment of relapsed or refractory peripheral T-cell lymphom...

2023-09-14 17:07 1573

Asieris' New Drug APL-1401 Completes First Administration in Patient with Moderately to Severely Active UC

SHANGHAI, Sept. 14, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its oral drug APL-1401 for the tr...

2023-09-14 16:54 1546

Nona Biosciences Expands Antibody Discovery Collaboration with BeiGene

CAMBRIDGE, Mass., Sept. 14, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting edge antibody technology innovation and provider of integrated antibody discovery and development solutions from "Idea to IND" (I to I™), announced an agreeme...

2023-09-14 16:00 1491

Neoss® Group launches NeoTell™ a new device to measure implant stability.

ZÜRICH, Sept. 14, 2023 /PRNewswire/ -- Earlier this year, Neoss Group, a pioneer in dental implant solutions, announced a partnership with Osstell AB, a global leader in implant stability measurement and osseointegration progress monitoring. Today, we proudly introduce the first fruit of this col...

2023-09-14 16:00 1643

Innovative Collaboration: Buzzreach and Oncoshot Spearhead Clinical Trial Advancements in Japan

SINGAPORE, Sept. 14, 2023 /PRNewswire/ -- Buzzreach and Oncoshot, two prominent entities in the clinical trials domain, have announced an impactful collaboration to accelerate clinical trials inJapan. The former specialises in clinical trial site recruitment and retention and project managemen...

2023-09-14 10:00 2550

Avasa raises $1.55M in oversubscribed funding round with innovative implantable devices

MIAMI and AUCKLAND, New Zealand, Sept. 14, 2023 /PRNewswire/ -- Avasa, a medical device pioneer advancing surgical techniques for improved patient outcomes, announces the successful completion of its recent funding, raising an impressive$1.55 million in capital investment. The influx of new inves...

2023-09-14 04:50 1986

AWAK TECHNOLOGIES RAISES US$20+ MILLION, READYING ITS WEARABLE DIALYSIS DEVICE FOR US-BASED PIVOTAL TRIAL

* AWAK closes one of the largest MedTech fundraise in 2023 in Southeast Asia * The Series B round was co-led by new investor Lion X Ventures and long-term investor Vickers Venture Partners, along with other new and existing investors * AWAK's ultra-portable peritoneal dialysis system enables ...

2023-09-13 21:27 2497

S-Patch Ex, Wearable ECG Patch, Cleared by US FDA

* Lightest weighing ECG patch in the market designed for comfort and ease of use * Embedded with Samsung's Next-Generation bio-processor proven to capture world's most accurate ECG waveforms SEOUL, South Korea, Sept. 13, 2023 /PRNewswire/ -- Wellysis, a spin-off company from Samsung SDS, has ...

2023-09-13 21:00 1924

Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor

— ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1  identified through Insilico Medicine's artificial intelligence (AI) platform, with potent activity in BRCA-mutated tumor models — — In May 2023, the U.S. Food and Drug Administration (FDA) cleared Insilico's I...

2023-09-13 20:29 1959

Asieris Announces Positive Interim Analysis Results in Phase II Clinical Trial of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer

SHANGHAI, Sept. 13, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the clinical trial of oral APL-12...

2023-09-13 19:09 1529

J INTS BIO, WCLC 2023 - Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI

SEOUL, South Korea, Sept. 13, 2023 /PRNewswire/ -- J INTS BIO announced that Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' was presented at the 2023 IASLC World Conference on Lung Cancer held inSingapore from 9th to 12th September, during the official session...

2023-09-13 15:58 1697

Zuberitamab (Anruixi®), the first domestically developed anti-CD20 antibody as a Class I innovative drug from BioRay Pharmaceutical, has been approved for marketing in China

SHANGHAI, Sept. 13, 2023 /PRNewswire/ -- Recently, BioRay Pharmaceutical Co., Ltd.  (hereinafter referred to as "Bioray") announced that its independently developed Class I innovative therapeutic biological product, Zuberitamab Injection (trade name: Anruixi®), indicated for the treatment of CD20...

2023-09-13 14:24 1492

Caliway Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of Over 50% and Reduced Pain by 4.7

-       CBL-0201DD Phase 2 study met the primary and all secondary endpoints. -       64.5% of painful lipomas showed complete clearance or dimensions reduction of more than 50% after CBL-514 treatments. -       54.8% of painful lipomas showed complete clearance or dimension reduction of more th...

2023-09-13 13:42 1388

AIRS Medical Inc. receives MDSAP Certification, Paving the Way for Global Expansion

SEOUL, South Korea, Sept. 13, 2023 /PRNewswire/ -- AIRS Medical Inc., an AI-powered healthcare solution provider headquartered in Korea announces the attainment of MDSAP (Medical Device Single Audit Program) certification. This milestone achievement underscores AIRS Medical's commitment to qualit...

2023-09-13 12:44 1433

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

SINGAPORE, Sept. 13, 2023 /PRNewswire/ -- Menarini Asia-Pacific has entered into a long-term exclusive licensing partnership with Astellas Pharma Inc. (Astellas) for the development, manufacturing and commercialization of the orally administered Janus kinase (JAK) inhibitor Smyraf® 50 mg and 100 ...

2023-09-13 10:30 2607

Maxigen Biotech Inc. Wins 2023 Asia's Leading SMEs Award for Innovative Sustainability

KUALA LUMPUR, Malaysia, Sept. 13, 2023 /PRNewswire/ -- Maxigen Biotech Inc.(MBI), a pioneering biotech company headquartered inTaiwan, has been honored with the prestigious 2023 Asia's Leading SMEs Award by ACES underscoring its commitment to innovation and sustainable operations.

2023-09-13 09:30 2147

GemPharmatech's Board Appoints Brandy Wilkinson, Ph.D. as its New Chief Executive Officer of GemPharmatech LLC.

SAN DIEGO, Sept. 12, 2023 /PRNewswire/ -- GemPharmatech LLC., a leading contract research organization, announced today that its Board of Directors has appointed Dr.Brandy Wilkinson as the Chief Executive Officer of its subsidiary inthe United States, effective September 12, 2023.

2023-09-13 00:00 1689

Frost & Sullivan Recognizes Suki AI with the 2023 North American Technology Leadership Award

Suki's innovative AI Assistant brings the power of Generative AI to health systems and delivers strong ROI SAN ANTONIO, Sept. 12, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the healthcare voice assistant industry and, based on its findings, recognizesSuki AI with the 2023 North Am...

2023-09-12 22:00 1846

TMRW Life Sciences Receives CE Mark for the CryoRobot Select, its Next-Generation Automated Platform to Safely Manage and Store Frozen Eggs and Embryos

TMRW's Cutting-Edge Technology is Raising the Standard of Care in Global Fertility NEW YORK, Sept. 12, 2023 /PRNewswire/ -- TMRW Life Sciences, a fertility technology company automating the IVF lab, today announced that it has received a CE Mark for the CryoRobot Select (CRS). The European desig...

2023-09-12 21:01 1743

Standigm's "Green Ribbon Campaign" to support Mitochondria Disease Awareness Week

SEOUL, South Korea, Sept. 12, 2023 /PRNewswire/ -- On September 5th, 2023 Standigm, a company using artificial intelligence (AI) technology for drug discovery and development launched, the "Green Ribbon Campaign," event to support the upcoming Mitochondrial Disease Awareness Week scheduled for Se...

2023-09-12 21:00 1457
1 ... 153154155156157158159 ... 614